At least two vaccine doses were administered to patients 1 and 2 before additional patients could be vaccinated. Dose level 1 (lowest dose) included five patients (500 µg total peptide, target 50 µg/peptide), three patients were included at dose level 2 (1000 µg total peptide, target 100 µg/peptide), and four patients at dose level 3 (2000 µg total peptide, target 200 µg/peptide). The initial individual peptide dose was chosen based on formulation studies and experience from another CAF09b adjuvanted cancer Figure 1 Clinical setup and response. (A) Clinical setup; biopsy, PET/CT scan, and blood samples were collected at baseline (T1). Treatment with aPD1 was either initiated around the first biopsy (group A) or had already been initiated for at least 4 months before the biopsy (group B: *). EVX- 01 vaccination was administered approximately at weeks 6–8 and every second week for six vaccinations in total (3 IM+3 IP). Tumor biopsies were performed (if possible) at T2 and T4. In addition, radiographic imaging was done every 12 weeks. Blood samples were collected from T1 to T4, and thereafter every 12 weeks. Figure created with BioRender.com. (B) Overview of patients included in trial: checkpoint inhibitor (CPI) initiation, baseline biopsy (day 0), vaccine treatment, and follow- up information of the twelve patients at three different dose levels. Small blue and green dots indicate either IP vaccinations or IM vaccinations, respectively. The depiction of disease condition and patient status are indicated in various colors. CR, complete response (green); IM, intramuscular; IP , intraperitoneal; MR, mixed response (salmon); PD, progressive disease (red); PR, partial response (blue); SD, stable disease (purple); PET, positron emission tomography. 4 Mørk SK, et al.